Drug development for recurrent and refractory classical Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 50, Issue 4, 2009, Pages 529-540

  Wildes, Tanya M ^a   Bartlett, Nancy L ^b  

^a Department of Medicine   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapeutic approaches; Immunotherapeutic approaches; Lymphoma and Hodgkin disease; Pharmacotherapeutics

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; DACARBAZINE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GALIXIMAB; GEMCITABINE; HCD 122; IFOSFAMIDE; IMMUNOTOXIN LMB2; LENALIDOMIDE; MAFOSFAMIDE; MDX 060; MONOCLONAL ANTIBODY; NAVELBINE; PE 38; PLACEBO; RITUXIMAB; SGN 30; SGN 40; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VORINOSTAT; XMAB 2513;

ADULT RESPIRATORY DISTRESS SYNDROME; ANEMIA; ANOREXIA; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CARDIOMYOPATHY; CHEST TIGHTNESS; CLASSICAL HODGKIN LYMPHOMA; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EPISTAXIS; FATIGUE; FEVER; HEART TAMPONADE; HERPES; HODGKIN DISEASE; HUMAN; HYPOTENSION; INJECTION SITE REACTION; LUNG TOXICITY; MULTIPLE MYELOMA; NEUROPATHY; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PSORIASIS; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; WHEEZING;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; IMMUNOTOXINS; NEOPLASM RECURRENCE, LOCAL;

EID: 68449100027     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902756586     Document Type: Review

References (84)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Linch DC, Goldstone AH, McMillan A, Chopra R, Vaughan Hudson G, Winfield D, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993;341:1051-1054.
3. Schmitz N, Haverkamp H, Josting A, Diehl V, Pfistner B, Carella AM, et al. Long term follow up in relapsed Hodgkin's disease (HD): Updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoetic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT) [abstract]. J Clin Oncol ASCO Annual Meeting Proceedings 2005;23:6508.
4. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 2002;359:2065-2071.
5. Lin TS, Avalos BR, Penza SL, Marcucci G, Elder PJ, Copelan EA. Second autologous stem cell transplant for multiply relapsed Hodgkin's disease. Bone Marrow Transplant 2002;29:763-767.
6. Vandenberghe E, Pearce R, Taghipour G, Fouillard L, Goldstone A. Role of a second transplant in the management of poor-prognosis lymphomas: A report from the European Blood and Bone Marrow Registry. J Clin Oncol 1997; 15:1595-1600.
7. Thomson KJ, Peggs KS, Smith P, Chopra R, Cavet J, Hunter A, et al. Improved outcome following reduced intensity allogeneic transplantation in Hodgkin's lymphoma relapsing post-autologous transplantation. ASH Annu Meet Abstr 2005;106:657.
8. Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26:455-462.
9. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003;98:310-314.
10. Wedgwood AR, Fanale MA, Fayad LE, McLaughlin P, Hagemeister FB, Pro B, et al. Rituximab + ABVD improves event-free survival (EFS) in patients with classical Hodgkin lymphoma in all International prognostic score (IPS) groups and in patients who have PET positive disease after 2-3 cycles of therapy. ASH Annu Meet Abstr 2007;110:215.
11. Tepler I, Schwartz G, Parker K, Charette J, Kadin ME, Woodworth TG, et al. Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: Complete response in a patient with Hodgkin's disease refractory to chemotherapy. Cancer 1994;73:1276-1285.
12. LeMaistre CF, Saleh MN, Kuzel TM, Foss F, Platanias LC, Schwartz G, et al. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998;91:399-405.
13. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, et al. Phase I trial of recombinant immunotoxin anti-tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000;18:1622-1636.
14. Engert A, Diehl V, Schnell R, Radszuhn A, Hatwig M-T, Drillich S, et al. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 1997;89:403-410.
15. Schnell R, Borchmann P, Staak JO, Schindler J, Ghetie V, Vitetta ES, et al. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol 2003;14:729-736.
16. Bartlett NL, Younes A, Carabasi MH, Forero A, Rosenblatt JD, Leonard JP, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008;111:1848-1854.
17. Leonard JP, Rosenblatt JD, Bartlett NL, Gopal A, Younes A, Fisher D, et al. Phase II study of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent Hodgkin's disease. ASH Annu Meet Abstr 2004;104:2635.
18. Leonard JP, Younes A, Rosenblatt JD, Gopal A, Pinter-Brown LC, Bartlett NL, et al. Targeting CD30 as therapy for Hodgkin's disease. Phase II results with the monoclonal antibody SGN-30. J Clin Oncol ASCO Annual Meeting Proceedings 2005;23:2553 [Abstract].
19. Blum KA, Johnson JL, Jung S, Cheson BD, Bartlett NL. Serious pulmonary toxicity with SGN-30 and gemcitabine, vinorelbine, and liposomal doxorubicin in patients with relapsed/refractory Hodgkin lymphoma (HL): cancer and leukemia group B (CALGB) 50502 ASH Annu Meet Abstr 2008;112:232.
20. Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007;25:2764-2769.
21. Renner C, Hartmann F, Pfreundschuh M. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Cancer Immunol Immunother 1997;45:184-186.
22. Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B, et al. Treatment of refractory Hodgkin' disease with an anti-CD16/CD30 bispecific antibody. Blood 1997; 89:2042-2047.
23. Hartmann F, Renner C, Jung W, da Costa L, Tembrink S, Held G, et al. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: Role of infusion schedule and costimulation with cytokines. Clin Cancer Res 2001;7:1873-1881.
24. Borchmann P, Schnell R, Fuss I, Manzke O, Davis T, Lewis LD, et al. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood 2002;100:3101-3107.
25. Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, et al. A phase I study with an anti-CD30 ricin Achain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res 2002;8:1779-1786.
26. Falini B, Flenghi L, Aversa F, Barbabietola G, Martelli MF, Comeli P, et al. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 1992;339: 1195-1196.
27. Younes A, Forero-Torres A, Bartlett NL, Leonard JP, Lynch C, Kennedy DA, et al. Multiple complete responses in a phase 1 dose-escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas. ASH Annu Meet Abstr 2008; 112:1006.
28. Younes A, Forero-Torres A, Bartlett NL, Leonard JP, Rege B, Kennedy DA, et al. Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma. J Clin Oncol 2008 ASCO Annual Meeting Proceedings 2008;26:8526 [Abstract].
29. Schnell R, Dietlein M, Staak JO, Borchmann P, Schomaecker K, Fischer T, et al. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti- CD30 monoclonal antibody. J Clin Oncol 2005;23:4669-4678.
30. Lenhard RE Jr, Order SE, Spunberg JJ, Asbell SO, Leibel SA. Isotopic immunoglobulin: A new systemic therapy for advanced Hodgkin's disease. J Clin Oncol 1985;3:1296-1300.
31. Vriesendorp H, Herpst J, Germack M, Klein J, Leichner P, Loudenslager D, et al. Phase I-II studies of yttrium-labeled antiferritin treatment for end- stage Hodgkin's disease, including Radiation Therapy Oncology Group 87- 01. J Clin Oncol 1991;9:918-928.
32. Decaudin D, Levy R, Lokiec F, Madar O, Brossel R, Morschhauser F, et al. Radioimmunotherapy (RIT) of refractory or relapsed Hodgkin's lymphoma (HL) with 90- Yttrium-labelled antiferritin antibody. ASH Annu Meet Abstr 2007;110:4473.
33. Vriesendorp HM, Quadri SM, Wyllie CT, Lai J, Borchardt PE, Harris L, et al. Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease. Clin Cancer Res 1999;5:3324s-3329s.
34. Herpst J, Klein J, Leichner P, Quadri S, Vriesendorp H. Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment. J Clin Oncol 1995;13:2394-2400.
35. Cerveny CG, Law CL, McCormick RS, Lenox JS, Hamblett KJ, Westendorf LE, et al. Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics. Leukemia 2005;19:1648-1655.
36. Carbone A, Gloghini A, Gattei V, Aldinucci D, Degan M, De Paoli P, et al. Expression of functional CD40 antigen on Reed- Sternberg cells and Hodgkin's disease cell lines. Blood 1995;85:780-789.
37. Murray PG, Oates J, Reynolds GM, Crocker J, Young LS. Expression of B7 (CD80) and CD40 antigens and the CD40 ligand in Hodgkin's disease is independent of latent Epstein- Barr virus infection. Clin Mol Pathol 1995;48:M105-M108.
38. Wahl AF, Klussman K, Thompson JD, Chen JH, Francisco LV, Risdon G, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2002;62:3736-3742.
39. Cerveny CG, Law C-L, McCormick RS, Lenox JS, Hamblett KJ, Westendorf LE, et al. The anti-CD30 monoclonal antibody SGN-30 inhibits Hodgkins disease growth and sensitizes cells to established chemotherapeutics. ASH Annu Meet Abstr 2004;104:2639.
40. Borchmann P, Treml JF, Hansen H, Gottstein C, Schnell R, Staak O, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood 2003;102:3737-3742.
41. Heuck F, Ellermann J, Borchmann P, Rothe A, Hansen H, Engert A, et al. Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines. J Immunother 2004;27:347-353.
42. Boll B, Hansen H, Heuck F, Reiners K, Borchmann P, Rothe A, et al. The fully human anti-CD30 antibody 5F11 activates NF-κB and sensitizes lymphoma cells to bortezomib-induced apoptosis. Blood 2005;106:1839-1842.
43. Pogge E, Boell B, Tawadros S, Reiners K, Borchmann P, Hansen H, et al. The human anti-CD30 antibody 5F11 activates NF-κB and sensitizes lymphoma cells to bortezomib induced apoptosis. ASH Annu Meet Abstr 2004;104:3295.
44. Hammond PW, Vafa O, Jacinto J, Vielmetter J, Karki S, Yoder S, et al. A humanized anti-CD30 monoclonal antibody, XmAb2513, with enhanced in vitro potency against CD30- positive lymphomas mediated by high affinity Fc-receptor binding. ASH Annu Meet Abstr 2005;106:1470.
45. Available at: http://clinicaltrials.gov. [Internet]; accessed 15 January 2009.
46. Jones RJ, Lin L, Gocke C, Hensley K, Siedner M, Barber JP, et al. Clonotypic B cells circulate in Hodgkin's lymphoma (HL). ASH Annu Meet Abstr 2006;108:470.
47. Long L, Patawaran M, Tong X, Kantak S, Aukerman SL, Pryer N, et al. Efficacy of an antagonistic anti-CD40 monoclonal antibody, HCD122 (CHIR-12.12), in preclinical models of human non-Hodgkin's lymphoma and Hodgkin's disease. Blood (ASH Annu Meet Abstr) 2006;108:230 [Abstract].
48. Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 2005;65:8331-8338.
49. Law C-L, McEarchern JA, Cerveny CG, Smith LM, Nesterova A, Gordon KA, et al. The humanized anti-CD40 monoclonal antibody SGN-40 targets Hodgkin's disease cells through multiple mechanisms. ASH Annu Meet Abstr 2005;106:1476.
50. Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Harrop K, Drachman JG, et al. A humanized antibody against CD40 (SGN-40) is well tolerated and active in non-Hodgkin's lymphoma (NHL): Results of a phase I study. J Clin Oncol 2006 ASCO Annual Meeting Proceedings 2006;24:7534 [Abstract].
51. Leonard JP, Friedberg JW, Younes A, Fisher D, Gordon LI, Moore J, et al. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007;18:1216-1223.
52. Vooijs WC, Otten HG, van Vliet M, van Dijk AJ, de Weger RA, de Boer M, et al. B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease. Br J Cancer 1997;76:1163-1169.
53. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti- CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-1465.
54. Hamblett KJ, Barton J, Cerveny CG, Andreyka JB, Kissler KM, Okeley NM, et al. SGN-35, an anti-CD30 antibody-drug conjugate, exhibits potent antitumor activity for the treatment of CD30+malignancies. ASH Annu Meet Abstr 2005;106:610.
55. Menzel C, Schirrmann T, Konthur Z, Jostock T, Dubel S. Human antibody RNase fusion protein targeting CD30+ lymphomas. Blood 2008;111:3830-3837.
56. Bierman P, Vose J, Leichner P, Quadri S, Armitage J, Klein J, et al. Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease. J Clin Oncol 1993;11: 698-703.
57. O'Mahony D, Janik J, Carrasquillo J, Seam P, Fiorillo J, Stewart D, et al. Yttrium-90 radiolabeled humanized monoclonal antibody to CD25 in refractory and relapsed Hodgkin's lymphoma. ASH Annu Meet Abstr 2008;112:231.
58. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-kB/Rel activation in Hodgkin/ Reed-Sternberg cells. Oncogene 1999;18:943-953.
59. Zheng B, Georgakis GV, Li Y, Bharti A, McConkey D, Aggarwal BB, et al. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-κB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 2004;10:3207-3215.
60. Younes A, Pro B, Romaguera J, Dang N. Safety and efficacy of Bortezomib (Velcade) for the treatment of relapsed classical Hodgkin's disease. ASH Annu Meet Abstr 2004; 104:2638.
61. Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206. Leuk Lymphoma 2007; 48:1313-1319.
62. Trelle S, Sezer O, Naumann R, Rummel M, Keller U, Nickelsen M, et al. Bortezomib is not active in patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study. ASH Annu Meet Abstr 2006;108:2477.
63. Friedberg JW, Kelly J, Voci S, Marquis D, Rich L, Rossi R, et al. Bortezomib and gemcitabine in relapsed Hodgkin lymphoma (HL). ASH Annu Meet Abstr 2007;110:2325.
64. Fanale M, Fayad L, Pro B, Samaniego F, Zachariah G, Nunez C, et al. A phase I study of Bortezomib in combination with ICE (BICE) in patients with relapsed/refractory classical Hodgkin lymphoma. ASH Annu Meet Abstr 2008;112:3048.
65. Kuruvilla J, Song K, Mollee P, Panzarella T, McCrae J, Nagy T, et al. A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. Hematology 2006;11:25-29.
66. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008;26:1544-1552.
67. Fehniger T, Larson S, Trinkaus K, Siegel M, DiPersio J, Cashen A, et al. A phase II multicenter study of lenalidomide in patients with relapsed or refractory classical Hodgkin lymphoma (cHL): Preliminary results. ASH Annu Meet Abstr 2008;112:2595.
68. Kuruvilla J, Taylor D, Wang L, Blattler C, Keating A, Crump M. Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin lymphoma. ASH Annu Meet Abstr 2008;112:3052.
69. Georgakis GV, Yazbeck VY, Li Y, Younes A. The histone deacetylase inhibitor vorinostat (SAHA) induces apoptosis and cell cycle arrest in Hodgkin lymphoma (HL) cell lines by altering several survival signaling pathways and synergizes with doxorubicin, gemcitabine and bortezomib. ASH Annu Meet Abstr 2006;108:2260.
70. Kirschbaum MH, Goldman BH, Zain JM, Cook JR, Rimsza LM, Forman SJ, et al. Vorinostat (suberoylanilide hydroxamic acid) in relapsed or refractory Hodgkin lymphoma: SWOG 0517. ASH Annu Meet Abstr 2007;110:2574.
71. Younes A, Pro B, Fanale M, McLaughlin P, Neelapu S, Fayad L, et al. Isotype-selective HDAC inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical Hodgkin lymphoma (HL). ASH Annu Meet Abstr 2007; 110:2566.
72. Bociek RG, Kuruvilla J, Pro B, Wedgwood A, Li Z, Drouin M, et al. Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/ refractory classical Hodgkin lymphoma (HL). J Clin Oncol 2008 ASCO Annual Meeting Proceedings 2008;26:8507 [Abstract].
73. Viviani S, Bonfante V, Fasola C, Valagussa P, Gianni AM. Phase II study of the histone-deacetylase inhibitor ITF2357 in relapsed/refractory Hodgkin's lymphoma patients. J Clin Oncol 2008 ASCO Annual Meeting Proceedings 2008;26: 8532 [Abstract].
74. Carlo-Stella C, Guidetti A, Viviani S, Bonfante V, Valagussa P, Marchiano A, et al. Phase II trial of combination of the histone deacetylase inhibitor ITF2357 and meclorethamine demonstrates clinical activity and safety in heavily pretreated patients with relapsed/ refractory Hodgkin lymphoma (HL) ASH Annu Meet Abstr 2008;112:2586.
75. Ottmann OG, Spencer A, Prince HM, Bhalla KN, Fischer T, Liu A, et al. Phase IA/II study of oral panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies. ASH Annu Meet Abstr 2008;112:958.
76. Jundt F, Raetzel N, Muller C, Calkhoven CF, Kley K, Mathas S, et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein β and NF-κB activity in Hodgkin and anaplastic large cell lymphomas. Blood 2005;106:1801-1807.
77. Johnston PB, Ansell SM, Colgan JP, Habermann TM, Inwards DJ, Micallef INM, et al. mTOR inhibition for relapsed or refractory Hodgkin lymphoma: promising single agent activity with everolimus (RAD001). ASH Annu Meet Abstr 2007;110:2555.
78. Herbst H, Dallenbach F, Hummel M, Niedobitek G, Pileri S, Muller-Lantzsch N, et al. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci USA 1991;88:4766-4770.
79. Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, Davis AR, et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 2003;101: 1905-1912.
80. Duraiswamy J, Sherritt M, Thomson S, Tellam J, Cooper L, Connolly G, et al. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood 2003;101:3150-3156.
81. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr Virus + Hodgkin's disease. J Exp Med 2004; 200:1623-1633.
82. Bollard CM, Huls HM, Straathof KC, Gottschalk SM, Lopez T, Chang C-C, et al. LMP2-cytotoxic T lymphocyte therapy for relapsed EBV positive lymphoma. ASH Annu Meet Abstr 2004;104:3276.
83. Bollard CM, Buza E, Huls H, Lopez T, Gottschalk S, Carrum G, et al. The use of autologous LMP2-specific cytotoxic T lymphocytes (CTL) for the treatment of relapsed EBV-positive Hodgkin disease and non-Hodgkin lymphoma. ASH Annu Meet Abstr 2005;106:773.
84. Bollard CM, Stanojevic M, Leen AM, Lopez T, Sheehan A, Carrum G, et al. Complete tumor responses in lymphoma patients who receive autologous cytotoxic T lymphocytes targeting EBV latent membrane proteins. ASH Annu Meet Abstr 2008;112:230.